Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Jean Hoffman‐Censits et al.|The Lancet|2016Cited by 3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerSusan Halabi, Nicholas J. Vogelzang, Eric J. Small et al.|Journal of Clinical Oncology|2003Cited by 678
Intermittent versus Continuous Androgen Deprivation in Prostate CancerMaha Hussain, Ian M. Thompson, Celestia S. Higano et al.|New England Journal of Medicine|2013Cited by 568
Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Eric J. Small, Nicholas J. Vogelzang, Susan Halabi et al.|Journal of Clinical Oncology|2004Cited by 502